What It Is
SLU-PP-332 is widely searched as a "peptide," but published scientific sources describe it more precisely as a synthetic small-molecule agonist of the estrogen-related receptors (ERRα, ERRβ, and ERRγ), not a conventional amino-acid-chain peptide drug.[1] ERRs are nuclear receptors related to classical estrogen receptors by structure, but they function independently in the transcriptional control of energy metabolism rather than as hormone receptors in the reproductive sense.
It originates from academic pharmacology research into "exercise mimetics" — compounds designed to reproduce specific molecular effects of exercise — and remains an early-stage laboratory research compound. It is not a marketed supplement, an approved drug, or a peptide in the strict biochemical sense, despite how it is often labeled in consumer content.
How It Works
As an ERR agonist, SLU-PP-332 is proposed to activate transcriptional programs that ERRs normally regulate, particularly genes involved in mitochondrial biogenesis, oxidative phosphorylation, and fatty acid oxidation in skeletal muscle.[2] ERRα in particular works alongside the co-regulator PGC-1α, a well-established driver of mitochondrial adaptation to endurance training.
The underlying hypothesis is that pharmacologically switching on some of the same genetic programs activated by aerobic exercise could mimic aspects of endurance training. That is biologically plausible and consistent with earlier exercise-mimetic research on AMPK and PPARδ agonists in mice, but activating a pathway in a dish or a mouse is a long way from replicating the cardiovascular, neuromuscular, and systemic effects of actual physical activity.[3]
What the Research Shows
Essentially all direct evidence for SLU-PP-332 is preclinical: mouse studies have examined endurance capacity and fatty acid oxidation after ERR activation, and mechanistic work has characterized its receptor-binding and gene-expression effects.[4] No published human clinical trials of SLU-PP-332 have been identified in major trial registries, and there is no peer-reviewed human efficacy or safety data.
This places SLU-PP-332 at the earliest rung of the evidence ladder — chemistry and animal biology — well below the human pharmacokinetic studies, dose-ranging trials, and randomized controlled trials that would be needed before any claims about human endurance, metabolic health, or body composition could be considered established.
Safety & Side Effects
Because no approved label or completed human trial exists for SLU-PP-332, there is no authoritative accounting of human side effects, contraindications, or drug interactions.[5] Preclinical tolerability observations in animal models do not reliably predict human safety, and important unknowns include human pharmacokinetics, cardiovascular effects, reproductive safety, and long-term metabolic consequences of activating ERR signaling broadly across tissues.
Unapproved research-chemical sourcing adds a separate layer of risk: identity, purity, and dosing accuracy are not verified the way they would be for a regulated drug product.[6] The absence of documented risk should be read as an evidence gap, not a safety endorsement.
Regulatory Status
SLU-PP-332 is not listed as an FDA-approved drug in Drugs@FDA, has no EMA authorization, and has not completed the staged drug-development process (animal testing, IND application, human trials, regulatory review) that precedes approval.[5] It exists purely as an experimental research compound from academic laboratories, sold in the research-chemical market with no oversight of manufacturing quality or labeling accuracy.
Because it is not a peptide in the conventional sense, comparisons to approved peptide drugs or hormone therapies are misleading; its regulatory and evidentiary position is closer to an early-stage academic drug-discovery candidate than to any marketed peptide product.
The Exercise-Mimetic Angle
SLU-PP-332's popular framing as "exercise in a pill" captures real scientific interest but overstates current knowledge. Public health guidance continues to recommend actual physical activity for its well-documented cardiovascular, metabolic, musculoskeletal, and mental-health benefits, none of which a single receptor agonist has been shown to replicate.[3]
Researchers studying compounds like SLU-PP-332 are generally trying to isolate and understand specific metabolic pathways relevant to obesity, insulin resistance, or muscle wasting — not to create a replacement for exercise. Until human trials exist, claims that SLU-PP-332 improves endurance, burns fat, or replaces training should be treated as hypotheses, not conclusions.